Leo Cancer Care Raises $65 Million in Series D Funding
Leo Cancer Care, based in Middletown, Wisconsin, has announced the successful completion of a $65 million Series D funding round. The round was led by Yu Galaxy, with participation from Eventide Asset Management. This funding marks a significant step forward for the company, which is focused on revolutionizing cancer treatment through the development of upright patient positioning, a method backed by global research.
Company Overview
Leo Cancer Care aims to provide a more human-centered approach to cancer treatment. The company is leveraging research that supports the benefits of treating patients in an upright position, which can improve patient comfort and potentially enhance treatment outcomes.
Leadership and Vision
Stephen Towe, CEO of Leo Cancer Care, has been a driving force behind the company's mission to transform cancer care. "This funding will allow us to continue our research and development, bringing us closer to making upright cancer treatment a standard practice," Towe stated.
Strategic Investors
The Series D round was spearheaded by Yu Galaxy, a firm known for investing in groundbreaking healthcare technologies. Eventide Asset Management also contributed to the round, further strengthening Leo Cancer Care's financial backing.
Use of Funds
The $65 million raised will be utilized to advance the company's research and development efforts, particularly in enhancing their upright treatment technology. Additionally, funds will be allocated to expand their team and scale operations to meet increasing demand.
Conclusion
Leo Cancer Care's latest funding round underscores the growing interest and investment in innovative cancer treatment solutions. With the backing of Yu Galaxy and Eventide Asset Management, the company is well-positioned to make significant strides in the field of oncology, potentially changing the way cancer care is delivered worldwide.